Korean J Gastroenterol.  2017 Mar;69(3):199-201. 10.4166/kjg.2017.69.3.199.

The Role of Tenofovir on the Prevention of Hepatitis B Transmission in Mothers with High Viral Load

• Kwon JH

• KMID: 2383416
• DOI: http://doi.org/10.4166/kjg.2017.69.3.199

Abstract

No abstract available.

MeSH Terms

Hepatitis B*
Hepatitis*
Humans
Mothers*
Tenofovir*
Viral Load*
Tenofovir

Reference

References

1. Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med. 2016; 374:2324–2334.

2. Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol. 1977; 105:94–98.

3. Hepatitis B fact sheet no. 204. [Internet]. Geneva: World Health Organization (WHO);2016 Jul. [cited 2016 Jul 10]. Available from:. http://www.who.int/mediacentre/factsheets/fs204/en/.

4. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: World Health Organization (WHO);2015 Mar. [cited 2015 Mar 20]. Available from:. http://apps.-who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf.

5. Zou H, Chen Y, Duan Z, Zhang H, Pan C. Virologic factors associated with failure to passive-active immunoprophylaxis in infants born to HBsAg-positive mothers. J Viral Hepat. 2012; 19:e18–e25.

6. Zhang H, Pan CQ, Pang Q, Tian R, Yan M, Liu X. Telbivudine or lamivudine use in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-life practice. Hepatology. 2014; 60:468–476.

7. Pan CQ, Zou HB, Chen Y, et al. Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis B surface antigen-positive women to their infants. Clin Gastroenterol Hepatol. 2013; 11:1349–1355.

8. Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012; 10:520–526.

9. del Canho R, Grosheide PM, Schalm SW, de Vries RR, Heijtink RA. Failure of neonatal hepatitis B vaccination: the role of HBV-DNA levels in hepatitis B carrier mothers and HLA antigens in neonates. J Hepatol. 1994; 20:483–486.

10. Chen HL, Lee CN, Chang CH, et al. Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother-to-infant transmission of hepatitis B virus. Hepatology. 2015; 62:375–386.

11. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012; 57:167–185.

12. Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016; 63:261–283.

13. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016; 10:1–98.

14. Pan CQ, Han G, Wang Y. Prevention of peripartum hepatitis B transmission. [comments]. N Engl J Med. 2016; 375:1497–1498.

15. Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2016. [internet]. Wilmington (NC): Registry Coordinating Center;2016. [cited 2016 Jul 10]. Available from:. http://www.apregistry.com/forms/interim_report.pdf.

16. Yang FS. Prevention of peripartum hepatitis B transmission. [comments]. N Engl J Med. 2016; 375:1497.

17. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection, 2013. [Internet]. Geneva: World Health Organization (WHO);2013 Oct. [cited 2013 Oct 10]. Available from:. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf.

18. Jindal A, Singh A, Sarin SK. Prevention of peripartum hepatitis B transmission. [comments]. N Engl J Med. 2016; 375:1496–1497.